Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study.

European journal of clinical pharmacology - 1 Jan 1997

Spina E, Gitto C, Avenoso A, Campo G M, Caputi A P, Perucca E

Abstract excerpt

OBJECTIVE: The clinical relevance of the CYP2D6 oxidation polymorphism in the treatment of depression with desipramine (DMI) was studied prospectively in depressed outpatients. METHODS: After CYP2D6 phenotype determination with dextromethorphan, 31 patients were treated with oral DMI at a dosage of 100 mg per day for 3 weeks. At the end of the 3rd week of treatment, severity of depressive symptoms was assessed by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP2D6
Share to Depressive Disorder

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Dextromethorphan

Share to Oxidation-Reduction

Share to Phenotype

Share to Polymorphism, Genetic

Source

Identifiers

PMID: 9049581
DOI: 10.1007/s002280050220

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study.PMID 9049581Read ↗

Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patients.Semantic proximity Read ↗

Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients.Semantic proximity Read ↗

Metabolism of desipramine in Japanese psychiatric patients: the impact of CYP2D6 genotype on the hydroxylation of desipramine.Semantic proximity Read ↗

Investigation of the Differences in the Pharmacokinetics of CYP2D6 Substrates, Desipramine, and Dextromethorphan in Healthy African Subjects Carrying the Allelic Variants CYP2D6*17 and CYP2D6*29, When Compared with Normal Metabolizers.Semantic proximity Read ↗

Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study.Semantic proximity Read ↗

CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6.Semantic proximity Read ↗

CYP2D6 phenotyping with dextromethorphan.Semantic proximity Read ↗

The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults.Semantic proximity Read ↗

Dextromethorphan metabolic phenotyping in an Iranian population.Semantic proximity Read ↗

Phenobarbital induces the 2-hydroxylation of desipramine.Semantic proximity Read ↗

Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics.Semantic proximity Read ↗

CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.